Cancer and Mild Cognitive Impairment a Patient-Caregiver Behavioral Intervention

January 4, 2022 updated by: Duke University

A Patient-Caregiver Behavioral Intervention for Older Adults With Cancer and Mild Cognitive Impairment

The purpose of this study is to see whether programs that include both a patient and their spouse or a patient and family caregiver (known as a dyad) are helpful for families in which one member of the dyad has cancer and mild memory difficulties and/or concerns. Participant and their spouse or participant and their family caregiver will have six, 60-minute video-conference sessions which will be scheduled at their convenience. The investigator will loan participants a tablet computer (iPad) to use for videoconferencing and train the participant in its use. Participant and their spouse or participant and their family caregiver will complete three assessments - one before starting the sessions, one after the sixth session, and one after 1 month. Each assessment will include surveys, which the participant will complete separately from their spouse or family caregiver. For most people, it will take upwards of 2 - 4 months to complete this study.

Study Overview

Status

Withdrawn

Intervention / Treatment

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27705
        • Duke University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Patient inclusion criteria include:

  1. Patients with Stage I-IV breast, colon, rectal, or lung cancer (newly diagnosed within 6 months; age 65 or older.
  2. Participants must be living at home (either in her/his own home).
  3. Participants must be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
  4. Exhibit Mild Cognitive Impairment.
  5. Have an informal family caregiver.

Inclusion Criteria:

(Partner or family member) inclusion criteria include:

  1. Caregivers are 18 older.
  2. Be fluent in English and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions.
  3. Either co-reside with the patient or spend at least 3-4 hours day caregiving.
  4. Not exhibit cognitive impairment.

Exclusion Criteria for both patients and caregivers:

  1. Participant has visual or hearing impairments that preclude participation.
  2. Participant has dementia and do not have the capacity to participate.
  3. Have a serious untreated psychiatric illness as documented in medical chart review.
  4. The patient and the caregiver score less than a 3 on the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) on a scale 0 to 10 to screen for distress.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patient Caregiver Dyad
Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
Six sixty minute sessions that teaches participants distress and communication coping skills.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of completed sessions as measured by enrollment log
Time Frame: Up to 10 weeks
Up to 10 weeks
Number of participants who are satisfied with the intervention as measured by a score of 24 or greater on the CSQ-8
Time Frame: Up to 10 weeks.
The Client Satisfaction Questionnaire (CSQ-8) is a self report measure of satisfaction with health and behavioral services received. The CSQ-8 is measured on a four point Likert scale from 1 "Quite Dissatisfied" to 4 "Very Satisfied." Scores range from 8-32, with higher values indicating higher satisfaction.
Up to 10 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Distress as measured by the DASS-21
Time Frame: Up to 10 weeks.
The Depression, Anxiety, and Stress Scale (DASS-21) measure will be used for rating general distress across three emotional states of depression, anxiety, and stress. The measure has a total of 21 items. Scores range from 0- 63, with higher scores indicating greater distress.
Up to 10 weeks.
Change in Quality of Life as measured by the FACT-G
Time Frame: Up to 10 weeks.
The Functional Assessment of Cancer Therapy: General (FACT-G) measure will be used for rating quality of life. The measure has a total of 27 items. Scores range from 0-108, with higher scores indicating greater quality of life.
Up to 10 weeks.
Change in Communication Patterns as measured by the CPQ-SF
Time Frame: Up to 10 weeks.
The Communication Patterns Questionnaire Short-Form (CPQ-SF) will be used for rating communication patterns in a relationship. The measure has a total of 11 items. Scores range from 11-99, higher scores indicate a greater likelihood of using a particular communication pattern during conflict interactions.
Up to 10 weeks.
Change in Relationship Satisfaction as measured by the Mutuality Scale of the Family Care Inventory
Time Frame: Up to 10 weeks.
The Mutuality Scale of the Family Care Inventory will be used for rating mutual concerns and overall relationship satisfaction. The measure consists of 15 items. Scores range from 0-60, higher scores indicate greater relationship satisfaction.
Up to 10 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 15, 2022

Primary Completion (Anticipated)

November 30, 2026

Study Completion (Anticipated)

November 30, 2026

Study Registration Dates

First Submitted

March 29, 2021

First Submitted That Met QC Criteria

March 29, 2021

First Posted (Actual)

April 1, 2021

Study Record Updates

Last Update Posted (Actual)

January 19, 2022

Last Update Submitted That Met QC Criteria

January 4, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on COPE +

Subscribe